By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) announced it finished the placement of NPM-115, its GLP-1 (exenatide) ...
Medical Device Network on MSN1d
Vivani treats first patient with long-lasting drug implant for weight lossA day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...
Medical Device Network on MSN2d
Vivani Medical to spin-off neurostim business Cortigent as public companyVivani was created in 2022 when subdermal drug implant company Nano Precision Medical merged with implantable visual ...
Vivani Medical (Nasdaq:VANI) announced today that it successfully administered the first GLP-1 implant in its LIBERATE-1 ...
Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...
Vivani Medical, Inc. (NASDAQ:VANI) said it intends to spin off Cortigent, Inc., a division that develops brain implant ...
Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.
The company wants to create two focused companies dedicated to driving current and future value in their respective ...
Vivani Medical (VANI) announced that it intends to spin off Cortigent, a division that develops brain implant devices to help people recover ...
The Vivani Medical Inc. combination appears to be over less than three years since its inception after the company reported ...
Short interest in Vivani Medical Inc (NASDAQ:VANI) decreased during the last reporting period, falling from 300.99K to 279.35K. This put 0.82% of the company's publicly available shares short.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback